Prevalence of pulmonary histoplasmosis infection among Human Immunodeficiency Virus/Tuberculosis patients attending infectious diseases hospital, Kano, northwestern Nigeria
Accepted: 21 June 2023
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Histoplasmosis is a disease with a global distribution and hyperendemic zones. The severity of the sickness is determined by the number of conidia inhaled and the host’s cellular immune system’s performance. This study aimed to determine the prevalence of pulmonary histoplasmosis infection among Human Immunodeficiency Virus (HIV) / Tuberculosis (TB) patients attending an infectious diseases hospital in Kano, Nigeria. The study is a cross-sectional hospital study, in which 203 intervieweradministered questionnaires were distributed, sputum samples were collected, and fungal culture was carried out. Identification and antifungal susceptibility for the test isolates were done using microscopic examination and agar disc diffusion. Data were analyzed using the Statistical Package for Social Sciences (SPSS) version 22.0. The prevalence of histoplasmosis was 5.4%. Of the 67 (33.0%) samples collected from TB patients, only 5 (2.5%) were positive for Histoplasma capsulatum, and of the 75 (37.0%) samples collected from HIV patients, only 4 (2.0%) were positive. The findings highlight the need for developing better diagnostic tools that will promptly make the diagnosis of the infection, especially in developing countries. Histoplasmosis can present with symptoms similar to other respiratory diseases, which may lead to delays in treatment, and increase the financial burden of managing the infection on the patients.
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.